Open AccessTreatment of de novo acute myelogenous leukemia with recombinant granulocyte macrophage‐colony‐stimulating factor in combination with standard induction chemotherapy: Effect of granulocyte macrophage‐colony‐stimulating factor on white blood cell counts
Author(s) -
Valent Peter,
Sillaber Christian,
Geissler Klaus,
Andreeff Michael,
Tafuri Agostino,
Vieder Ludwig,
Schulz Gregor,
Lechner Klaus,
Bettelheim Peter
Publication year - 1992
Publication title -
medical and pediatric oncology
Language(s) - English
Resource type - Journals
eISSN - 1096-911X
pISSN - 0098-1532
DOI - 10.1002/mpo.2950200705
Subject(s) - medicine , granulocyte macrophage colony stimulating factor , myelopoiesis , chemotherapy , leukemia , immunology , granulocyte , aplasia , white blood cell , granulocyte colony stimulating factor , cancer research , haematopoiesis , biology , cytokine , stem cell , genetics
GM‐CSF is a major regulator of myelopoiesis. Recombinant human GM‐CSF (250 μg/m 2 per day i.v.) was used prior to chemotherapy (“3 + 7” scheme) to recruit leukemia blasts in vivo (de novo AML patients, n = 20) into the chemotherapy sensitive phases of the cell cycle. The stimulatory effect of GM‐CSF on peripheral blood AML blasts was associated with a rapid redistribution of leukemia blood cells and with an increase in “S‐phase positive” cells. Standard induction chemotherapy (“3 + 7”) following GM‐CSF induced complete aplasia in 19/20 patients. In the same patients, rhGM‐CSF (given after chemotherapy) was found to shorten the time of complete aplasia compared to historical controls whereas post‐chemotherapy‐ and follow‐up data suggest no significant differences for CCR and survival. Together, our studies show that GM‐CSF can safely be administered to AML patients in combination with induction chemotherpay to recruit leukemia cells into the cell cycle. © 1992 Wiley‐Liss, Inc.